Investors & Media

Press Releases

Investors & Media

Press Releases

Jun 04, 2023
Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma
May 30, 2023
Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference
May 25, 2023
Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 01, 2023
Day One Reports First Quarter 2023 Financial Results and Corporate Progress
Apr 26, 2023
Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 12, 2023
Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress
Mar 06, 2023
Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress
Feb 27, 2023
Day One to Participate in the Cowen 43rd Annual Health Care Conference
Jan 08, 2023
Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma
Displaying 11 - 19 of 19
Investor Contact

Investor Relations
investors@dayonebio.com

Media Contact

Laura Cooper
Media@dayonebio.com

Helpful Tools